Macrocyclic kinase inhibitors and uses thereof

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is a substituted or unsubstituted phenyl ring or a substituted or unsubstituted, monocyclic, 5- to 6-membered heteroaryl ring, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur;

each instance of R A is independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR A1 , —N(R A1 ) 2 , —SR A1 , —CN, —SCN, —C(═NR A1 )R A1 , —C(═NR A1 )OR A1 , —C(═NR A1 )N(R A1 ) 2 , —C(═O)R A1 , —C(═O)OR A1 , —C(═O)N(R A1 ) 2 , —NO 2 , —NR A1 C(═O)R A1 , —NR A1 C(═O)OR A1 , —NR A1 C(═O)N(R A1 ) 2 , —OC(═O)R A1 , —OC(═O)OR A1 , or —OC(═O)N(R A1 ) 2 , wherein each instance of R A1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two R A1 groups are joined to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring;

k is 0, 1, 2, 3 or 4;

L is a substituted or unsubstituted, saturated or unsaturated C 3-10 hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with —O—, —S—, —NR N —, —N═, or ═N—, wherein each instance of R N is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group;

R B is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group;

each of X A , X B , and X C is independently N or CR X , wherein R X is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR X1 , —N(R X1 ) 2 , —SR X1 , —CN, —SCN, —C(═NR X1 )R X1 , —C(═NR X1 )OR X1 , —C(═NR X1 )N(R X1 ) 2 , —C(═O)R X1 , —C(═O)OR X1 , C(═O)N(R X1 ) 2 , —NO 2 , —NR X1 C(═O)R X1 , —NR X1 C(═O)OR X1 , —NR X1 C(═O)N(R X1 ) 2 , —OC(═O)R X1 , —OC(═O)OR X1 , or —OC(═O)N(R X1 ) 2 , wherein each instance of R X1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two R X1 groups are joined to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring;

Y is —O— or —NR Y —, wherein R Y is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group;

or when Y is —NR Y — and X A is CR X , R Y and R X of X A are joined to form a substituted or unsubstituted, monocyclic, 5- to 7-membered heterocyclic ring that is fused with Ring B;

each instance of R C is independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR C1 , —N(R C1 ) 2 , —SR C1 , —CN, —SCN, —C(═NR C1 )R C1 , —C(═NR C1 )OR C1 , —C(═NR C1 )N(R C1 ) 2 , —C(═O)R C1 , —C(═O)OR C1 , —C(═O)N(R C1 ) 2 , —NO 2 , —NR C1 C(═O)R C1 , —NR C1 C(═O)OR C1 , —NR C1 C(═O)N(R C1 ) 2 , —OC(═O)R C1 , —OC(═O)OR C1 , or —OC(═O)N(R C1 ) 2 , wherein each instance of R C1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two R C1 groups are joined to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring;

m is 0, 1, 2, 3, 4 or 5; and

R D is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR D1 , —N(R D1 ) 2 , —SR D1 , —CN, —SCN, —C(═NR D1 )R D1 , —C(═NR D1 )OR D1 , —C(═NR D1 )N(R D1 ) 2 , —C(═O)R D1 , —C(═O)OR D1 , —C(═O)N(R D1 ) 2 , —NO 2 , —NR D1 C(═O)R D1 , —NR D1 C(═O)OR D1 , —NR D1 C(═O)N(R D1 ) 2 , —OC(═O)R D1 , —OC(═O)OR D1 , or —OC(═O)N(R D1 ) 2 , wherein each instance of R D1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R D1 are joined to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R X is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR X1 , —N(R X1 ) 2 , —SR X1 , —CN, —SCN, —C(═NR X1 )R X1 , —C(═NR X1 )OR X1 , —C(═NR X1 )N(R X1 ) 2 , —C(═O)R X1 , —C(═O)OR X1 , —C(═O)N(R X1 ) 2 , —NO 2 , —NR X1 C(═O)R X1 , —NR X1 C(═O)OR X1 , —NR X1 C(═O)N(R X1 ) 2 , —OC(═O)R X1 , —OC(═O)OR X1 , or —OC(═O)N(R X1 ) 2 , wherein each instance of R X1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two R X1 groups are joined to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring; and

R Y is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group.

3. The compound of claim 2 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 2 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

Y is —NR Y —;

X A is CR X ; and

R Y and R X of X A are joined to form a substituted or unsubstituted, monocyclic, 5- to 7-membered heterocyclic ring that is fused with Ring B.

6. The compound of claim 5 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof, wherein each instance of R E is independently hydrogen, halogen, or substituted or unsubstituted C 1-6 alkyl.

7. The compound of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring A is a substituted or unsubstituted phenyl ring.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one instance of R A is —OR A1 —.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is a substituted or unsubstituted, saturated or unsaturated C 5-6 hydrocarbon chain, wherein one or two chain atoms of the hydrocarbon chain are independently replaced with —O—, —S—, or —NR N —.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is of the formula:

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is —O—.

13. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Y is —NR Y —.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring C is of the formula:

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each instance of R C is independently halogen or unsubstituted C 1-6 alkyl.

16. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

19. A method of therapeutically treating an inflammatory disease in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the inflammatory disease is allergy, asthma, blepharitis, delayed-type hypersensitivity reaction, dermatomyositis, hay fever, immediate hypersensitivity reaction, inflammatory dermatosis, ocular inflammatory disease, pemphigoid, pemphigus, poison ivy dermatitis, psoriasis, scleroderma, systemic lupus erythematosus, uveitis, or vaginitis.

20. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one instance of R A is substituted or unsubstituted, monocyclic, 3- to 7-membered heterocyclyl, wherein one, two, or three atoms in the heterocyclic ring system are independently selected from the group consisting of nitrogen, oxygen, and sulfur.

21. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is of the formula:

22. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X A is CR X , and each of X B and X C is N.

23. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X C is CR X , and each of X A and X B is N.

24. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R B is hydrogen.

25. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

26. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

27. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

28. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

29. The compound of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

30. The compound of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

31. The compound of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

32. The compound of claim 6 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

33. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

34. The method of claim 19 , wherein:

R X is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR X1 , —N(R X1 ) 2 , —SR X1 , —CN, —SCN, —C(═NR X1 )R X1 ,—C(═NR X1 )OR X1 , —C(═NR X1 )N(R X1 ) 2 , —C(═O)R X1 , —C(═O)OR X1 , —C(═O)N(R X1 ) 2 , —NO 2 , —NR X1 C(═O)R X1 , —NR X1 C(═O)OR X1 , —NR X1 C(═O)N(R X1 ) 2 , —OC(═O)R X1 , —OC(═O)OR X1 , or —OC(═O)N(R X1 ) 2 , wherein each instance of R X1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two R X1 groups are joined to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring; and

R Y is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group.

35. The method of claim 19 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

36. The method of claim 19 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

37. The method of claim 19 , wherein the inflammatory disease is psoriasis.

38. The method of claim 19 , wherein the inflammatory disease is an inflammatory dermatosis.